Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06582875 · ClinicalTrials.gov registry record · Phase 2
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
A Phase 2 study of Obesity and Autosomal Dominant Polycystic Kidney, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 1
- Study location
NCT06582875 is a Phase 2 study of Obesity and Autosomal Dominant Polycystic Kidney that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 126 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06582875, a Phase 2 study of Obesity and Autosomal Dominant Polycystic Kidney, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.
Conditions Studied
Interventions
- DRUG Tirzepatide
- OTHER Placebo
Study Locations (1)
Colorado
- University of Colorado - Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06582875
The ClinicalTrials.gov registry entry for NCT06582875 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06582875 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06582875 about?
NCT06582875 is a clinical study titled "Glucagon-Like Peptide-1 Receptor Agonist in ADPKD". The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney dis...
What is the current status of trial NCT06582875?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2025-03-06. Estimated completion is 2029-06-30.
What conditions does trial NCT06582875 study?
This clinical trial studies the following conditions: Obesity, Autosomal Dominant Polycystic Kidney.
What interventions are being tested in trial NCT06582875?
The interventions under investigation include: Tirzepatide (DRUG), Placebo (OTHER).
Who is sponsoring clinical trial NCT06582875?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06582875 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.